Status:
RECRUITING
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
Photocure ASA
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method...
Detailed Description
Objectives are as follows: Primary i) Comparison of the reduction in MRD burden score between pre-resection and post-resection urine samples across BLC and WLC resection arms of the study, and among ...
Eligibility Criteria
Inclusion
- Patients undergoing TURBT for radiographic or cystoscopic positive tumor
- 18+ years old
- Upper tract evaluated using standard of care throughout duration of the study
- Induction intravesical therapy initiated within four weeks of TURBT
Exclusion
- Variant histology consisting of less than 50% urothelial carcinoma
- History, or current diagnosis, of upper tract tumor or muscle-invasive bladder cancer
- Prior history of pelvic radiation
- Active urinary tract infection (UTI)
- Patients who are noncompliant with the study protocol
Key Trial Info
Start Date :
December 20 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 4 2028
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06525571
Start Date
December 20 2024
End Date
January 4 2028
Last Update
November 18 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States, 20016
2
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21287